35 results

Richard Pops, chairman and chief executive officer of Alkermes. Photograph: Patrick  Fallon/Bloomberg

Irish drug group Alkermes has reported a 15 per cent rise in revenues for the fourth quarter. Sales jumped to $315.8 million in the fourth quarter. T(...)

Immatics Biotechnologies chairman Peter Chambre and Alkermes director Shane Cooke are to join the board of UDG Healthcare as non-executive directors. Photograph: David Sleator

Healthcare services provider UDG Healthcare has appointed two new non-executive directors to its board. Immatics Biotechnologies chairman Peter Chamb(...)

Alkermes chief executive Richard Pops said he was disappointed by the vote of the FDA advisory panel on its new drug for major depressive disorder. Photograph: Dara Mac Dónaill

An advisory panel to the US Food and Drug Administration voted against approving a treatment for depression developed by Irish-based company Alkermes (...)

Alkermes reckons more than eight million people in the US alone suffer from a major depressive disorder. File photograph: Getty Images

Shares in Irish biopharma group Alkermes jumped sharply after the United States Food and Drug Administration (FDA) agreed to reconsider a depression d(...)

Richard Pops, chairman and CEO of Alkermes:  The FDA  may want the company to run several expensive new trials before it reconsiders its decision.  Photograph: Patrick T Fallon/Bloomberg

Pulling success from the jaws of disaster is a fantastic plot twist. It’s just not always a good foundation for a biotech investment. Angling for an (...)

Richard Pops, chairman and chief executive officer of Alkermes. Photograph: Patrick Fallon/Bloomberg

Shares in Irish drug company Alkermes continued to slide as the company comes to terms with an FDA refusal to consider approval for a depression drug (...)

Alkermes’s proprietary products, Vivitrol and Aristada, both saw an increase in net sales in the first quarter

Alkermes made a pretax loss of $72.6 million (€66.8m) in the three months to the end of March 2017. That represents a decrease of 5.75 per cent on the(...)

Richard Pops, Alkermes chief executive, received a lower salary last year. Photograph: Dara Mac Dónaill / The Irish Times

Executives at Irish-headquartered biopharma group Alkermes received lower overall remuneration last year. The group, which is domiciled in Ireland fo(...)

A major highlight of the year ahead will be the Great Place to Work Conference in Dublin on September 21st

Great Place to Work hosts numerous events throughout the year. Some of these are onsite events which offer great opportunities to get insights into a (...)

Tony Ward, chairperson of the Save Roscommon campaign, in front of a sign welcoming drivers to Co Roscommon after driving over the bridge on the N4, a crossing point from Westmeath to Roscommon. Photograph: Alan Betson/The Irish Times

Co Roscommon is to remain intact following a controversial boundary review which looked at whether over 30 sq km of the south county should be subsume(...)

  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »